CompletedNCT06494397
VHX-896 and iloperidone levels at steady state
About this title
Read the official source — NCT06494397Medication studyAges 18–65United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Los Alamitos and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: July 11, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 26
- Sponsor
- Vanda Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06494397
- Official title
Show the full official title
Crossover Bioequivalence Study of 12 mg VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Alamitos · Gaithersburg · Marlton
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vanda Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including VHX-896 and iloperidone and Iloperidone and VHX-896.
Who was this study for?
Listed age limits: 18 years to 65 years.
